SHEETAL S SAWANT

Ms. SHEETAL S SAWANT

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2020 in Science Immunology
Verified
Journal Article
Open access
PDF file
SKSudhir Pai Kasturi
Sudhir Pai Kasturi
MRMohammed Ata Ur Rasheed
Mohammed Ata Ur Rasheed
CHColin Havenar-Daughton
Colin Havenar-Daughton
MPMathew Pham
Mathew Pham
TLTraci Legere
Traci Legere
BPBali Pulendran
Bali Pulendran
A fundamental challenge in vaccinology is learning how to induce durable antibody responses. Live viral vaccines induce antibody responses that last a lifetime, but those induced with subunit vaccines wane rapidly. Studies in mice and humans have established that long-lived plasma cells (LLPCs) in the bone marrow (BM) are critical mediators of durable antibody responses. Here, we present data that adjuvanting an HIV-1 clade C 1086.C–derived gp140 immunogen (Env) with a novel synthetic Toll-like receptor (TLR)–7/8 agonist named 3M-052 formulated in poly(lactic-co-glycolic)acid or PLGA nanoparticles (NPs) or with alum, either alone or in combination with a TLR-4 agonist GLA, induces notably high and persistent (up to ~1 year) frequencies of Env-specific LLPCs in the BM and serum antibody responses in rhesus macaques. Up to 36 and 18% of Env-specific cells among total IgG-secreting BM-resident plasma cells were detected at peak and termination, respectively. In contrast, adjuvanting Env with alum or GLA in NP induced significantly lower (~<100-fold) LLPC and antibody responses. Immune responses induced by 3M-052 were also significantly higher than those induced by a combination of TLR-7/8 (R848) and TLR-4 (MPL) agonists. Adjuvanting Env with 3M-052 also induced robust activation of blood monocytes, strong plasmablast responses in blood, germinal center B cells, T follicular helper (TFH) cells, and persistent Env-specific plasma cells in draining lymph nodes. Overall, these results demonstrate efficacy of 3M-052 in promoting high magnitude and durability of antibody responses via robust stimulation of innate immunity and BM-resident LLPCs.

1 November 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SNScott D. Neidich
Scott D. Neidich
YFYouyi Fong
Youyi Fong
SLShuying S. Li
Shuying S. Li
DGDaniel E. Geraghty
Daniel E. Geraghty
BWBrian D. Williamson
Brian D. Williamson
GTGeorgia Tomaras
Georgia Tomaras
HVTN 505 is a preventative vaccine efficacy trial testing DNA followed by recombinant adenovirus serotype 5 (rAd5) in circumcised, Ad5-seronegative men and transgendered persons who have sex with men in the United States. Identified immune correlates of lower HIV-1 risk and a virus sieve analysis revealed that, despite lacking overall efficacy, vaccine-elicited responses exerted pressure on infecting HIV-1 viruses. To interrogate the mechanism of the antibody correlate of HIV-1 risk, we examined antigen-specific antibody recruitment of Fcγ receptors (FcγRs), antibody-dependent cellular phagocytosis (ADCP), and the role of anti-envelope (anti-Env) IgG3. In a prespecified immune correlates analysis, antibody-dependent monocyte phagocytosis and antibody binding to FcγRIIa correlated with decreased HIV-1 risk. Follow-up analyses revealed that anti-Env IgG3 breadth correlated with reduced HIV-1 risk, anti-Env IgA negatively modified infection risk by Fc effector functions, and that vaccine recipients with a specific FcγRIIa single-nucleotide polymorphism locus had a stronger correlation with decreased HIV-1 risk when ADCP, Env-FcγRIIa, and IgG3 binding were high. Additionally, FcγRIIa engagement correlated with decreased viral load setpoint in vaccine recipients who acquired HIV-1. These data support a role for vaccine-elicited anti–HIV-1 Env IgG3, antibody engagement of FcRs, and phagocytosis as potential mechanisms for HIV-1 prevention.

18 September 2019 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
GGGlenda E. Gray
Glenda E. Gray
YHYing Huang
Ying Huang
NGNicole Grunenberg
Nicole Grunenberg
FLFatima Laher
Fatima Laher
SRSurita Roux
Surita Roux
LCLawrence Corey
Lawrence Corey
One of the most successful HIV vaccines to date, the RV144 vaccine tested in Thailand, demonstrated correlates of protection including cross-clade V1V2 immunoglobulin G (IgG) breadth, Env-specific CD4+ T cell polyfunctionality, and antibody-dependent cellular cytotoxicity (ADCC) in vaccinees with low IgA binding. The HIV Vaccine Trials Network (HVTN) 097 trial evaluated this vaccine regimen in South Africa, where clade C HIV-1 predominates. We compared cellular and humoral responses at peak and durability immunogenicity time points in HVTN 097 and RV144 vaccinee samples, and evaluated vaccine-matched and cross-clade immune responses. At peak immunogenicity, HVTN 097 vaccinees exhibited significantly higher cellular and humoral immune responses than RV144 vaccinees. CD4+ T cell responses were more frequent in HVTN 097 irrespective of age and sex, and CD4+ T cell Env-specific functionality scores were higher in HVTN 097. Env-specific CD40L+ CD4+ T cells were more common in HVTN 097, with individuals having this pattern of expression demonstrating higher median antibody responses to HIV-1 Env. IgG and IgG3 binding antibody rates and response magnitude to gp120 vaccine– and V1V2 vaccine–matched antigens were higher or comparable in HVTN 097 than in RV144 ADCC, and ADCP functional antibody responses were elicited in HVTN 097. Env-specific IgG and CD4+ Env responses declined significantly over time in both trials. Overall, cross-clade immune responses associated with protection were better than expected in South Africa, suggesting wider applicability of this regimen.

31 July 2025 in Science
Verified
Journal Article
Open access
TCTom G. Caniels
Tom G. Caniels
MPMadhu Prabhakaran
Madhu Prabhakaran
GOGabriel Ozorowski
Gabriel Ozorowski
KMKellie J. MacPhee
Kellie J. MacPhee
WWWeiwei Wu
Weiwei Wu
RSRogier W. Sanders
Rogier W. Sanders
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. In a double-blinded, placebo-controlled phase 1 human clinical trial, the recombinant, germline-targeting envelope glycoprotein (Env) trimer BG505 SOSIP.v4.1-GT1.1, adjuvanted with AS01 B , induced bnAb precursors of the VRC01-class at a high frequency in the majority of vaccine recipients. These bnAb precursors, which target the CD4 receptor binding site, had undergone somatic hypermutation characteristic of the VRC01-class. A subset of isolated VRC01-class monoclonal antibodies neutralized wild-type pseudoviruses and was structurally extremely similar to bnAb VRC01. These results further support germline-targeting approaches for human HIV vaccine design and demonstrate atomic-level manipulation of B cell responses with rational vaccine design.

1 September 2014 in Journal of Virology
Verified
Journal Article
Open access
PDF file
TPTamika L. Payne
Tamika L. Payne
JBJeff Blackinton
Jeff Blackinton
AFAlyse Frisbee
Alyse Frisbee
JPJoy Pickeral
Joy Pickeral
SSSHEETAL S SAWANT
SHEETAL S SAWANT
GTGeorgia Tomaras
Georgia Tomaras
The ability of CD8+T cells to effectively limit HIV-1 replication and block HIV-1 acquisition is determined by the capacity to rapidly respond to HIV-1 antigens. Understanding both the functional properties and regulation of an effective CD8+response would enable better evaluation of T cell-directed vaccine strategies and may inform the design of new therapies. We assessed the antigen specificity, cytokine signature, and mechanisms that regulate antiviral gene expression in CD8+T cells from a cohort of HIV-1-infected virus controllers (VCs) (400 cells/μl) capable of soluble inhibition of HIV-1. Gag p24 and Nef CD8+T cell-specific soluble virus inhibition was common among the VCs and correlated with substantial increases in the abundance of mRNAs encoding the antiviral cytokines macrophage inflammatory proteins MIP-1α, MIP-1αP (CCL3L1), and MIP-1β; granulocyte-macrophage colony-stimulating factor (GM-CSF); lymphotactin (XCL1); tumor necrosis factor receptor superfamily member 9 (TNFRSF9); and gamma interferon (IFN-γ). The induction of several of these mRNAs was driven through a coordinated response of both increased transcription and stabilization of mRNA, which together accounted for the observed increase in mRNA abundance. This coordinated response allows rapid and robust induction of mRNA messages that can enhance the CD8+T cells' ability to inhibit virus upon antigen encounter.IMPORTANCEWe show that mRNA stability, in addition to transcription, is key in regulating the direct anti-HIV-1 function of antigen-specific memory CD8+T cells. Regulation at the level of RNA helps enable rapid recall of memory CD8+T cell effector functions for HIV-1 inhibition. By uncovering and understanding the mechanisms employed by CD8+T cell subsets with antigen-specific anti-HIV-1 activity, we can identify new strategies for comprehensive identification of other important antiviral genes. This will, in turn, enhance our ability to inhibit virus replication by informing both cure strategies and HIV-1 vaccine designs that aim to reduce transmission and can aid in blocking HIV-1 acquisition.

29 October 2021 in Science Immunology
Verified
Journal Article
Closed access
LDLindsay C. Dahora
Lindsay C. Dahora
MVMarije K. Verheul
Marije K. Verheul
KWKatherine L. Williams
Katherine L. Williams
CJCelina Jin
Celina Jin
LSLisa Stockdale
Lisa Stockdale
GTGeorgia Tomaras
Georgia Tomaras
Prime-boost vaccination with S. Typhi Vi capsule induces convergent antibodies whose function depends on specificity and avidity.